Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Filings indexed 220 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Regulatory Filings
2026-04-28 English
424B5 - Sagimet Biosciences Inc. (0001400118) (Filer)
Prospectus
2026-04-28 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Regulatory Filings
2026-04-27 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Regulatory Filings
2026-04-27 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Regulatory Filings
2026-04-21 English
4 - SAGIMET BIOSCIENCES INC. (0001400118) (Filer)
Director's Dealing
2026-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.